NKTX

Nkarta, Inc. (NKTX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. The company operates as a single reporting segment and has no products approved for commercial sale. Its lead product candidate, NKX019, is in Phase 1/2 clinical trials (Ntrust-1 and Ntrust-2) for lupus nephritis, primary membranous nephropathy, systemic sclerosis, myositis, ANCA-associated vasculitis, and rheumatoid arthritis.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by $17.4 million for the three months ended June 30, 2026, compared to the same period in 2025. This was driven primarily by a $15.9 million increase in total operating expenses.
• Impairment Charges: A significant non-cash impairment charge of approximately $8.0 million was recorded in Q2 2026. This included $4.0 million for property and equipment (due to manufacturing optimization) and $4.1 million for right-of-use assets (due to subleasing unused space).
• R&D Spend Increase: Research and development expenses rose by $8.3 million quarter-over-quarter, primarily due to higher clinical spending and manufacturing costs for the NKX019 program.
• Interest Income Decline: Interest income decreased by $1.4 million quarter-over-quarter due to lower average investment balances and interest rates.
• Cost Containment: Despite increased R&D, personnel costs decreased in the six-month period due to a reduction in force (34% of workforce) executed in March 2025.

Guidance, Outlook, and Risks

• Clinical Progress: In April 2026, the company reached an agreement with the FDA on protocol amendments for Ntrust-1 and Ntrust-2 to enable outpatient administration (reducing monitoring from 24 to 2 hours) and to allow re-dosing. Enrollment in the second dose-escalation cohort has been authorized.
• Liquidity: Management believes current cash, cash equivalents, and investments ($243.2 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring significant losses and will require additional capital to advance clinical trials and commercialization.
• Capital Raising: The company filed a Shelf Registration Statement (S-3) in March 2026 covering up to $350 million in securities, including an "at-the-market" (ATM) program. No sales have been made under the ATM program as of June 30, 2026.
• Key Risks:
  • Deprioritized Programs: Development of NKX019 for B-cell malignancies and NKX101 has been deprioritized based on clinical data and competitive landscape.
  • Manufacturing: Reliance on a sole supplier (Miltenyi) for critical manufacturing equipment and reagents poses supply chain risks.
  • Regulatory: No cell therapies are currently approved for autoimmune diseases; regulatory pathways are novel and uncertain.
  • Enrollment: Patient enrollment in autoimmune trials remains challenging due to competition and the novelty of cell therapy in this space.

Investor Verification Checklist

• Verify the impact of the $8.0 million impairment charge on future depreciation and lease expense projections.
• Confirm the timeline for outpatient administration implementation in Ntrust-1 and Ntrust-2 trials following FDA protocol approval.
• Monitor cash burn rate relative to the $243.2 million liquidity position to assess the runway for future capital raises.
• Review the status of the CRISPR Therapeutics collaboration, noting that CRISPR opted out of the NKX070 program in September 2025 and both NKX070 and NK+T are currently deprioritized.
• Assess the risks associated with the sole supplier dependency for the Miltenyi CliniMACS Plus system and related reagents.